Display options
Cite
Nguyen LM, Singh AP, Wiczling P, et al. Dynamics of Erythropoietic Biomarkers in Response to Treatment With Erythropoietin in Belgrade Rats. Front Pharmacol. 2018;9:316doi: 10.3389/fphar.2018.00316.
Nguyen, L. M., Singh, A. P., Wiczling, P., & Krzyzanski, W. (2018). Dynamics of Erythropoietic Biomarkers in Response to Treatment With Erythropoietin in Belgrade Rats. Frontiers in pharmacology, 9316. https://doi.org/10.3389/fphar.2018.00316
Nguyen, Ly M, et al. "Dynamics of Erythropoietic Biomarkers in Response to Treatment With Erythropoietin in Belgrade Rats." Frontiers in pharmacology vol. 9 (2018): 316. doi: https://doi.org/10.3389/fphar.2018.00316
Nguyen LM, Singh AP, Wiczling P, Krzyzanski W. Dynamics of Erythropoietic Biomarkers in Response to Treatment With Erythropoietin in Belgrade Rats. Front Pharmacol. 2018 Apr 10;9:316. doi: 10.3389/fphar.2018.00316. eCollection 2018. PMID: 29692726; PMCID: PMC5902559.
Copy Download .nbib Format: NLM
Share it on

Front Pharmacol. 2018 Apr 10;9:316. doi: 10.3389/fphar.2018.00316. eCollection 2018.

Dynamics of Erythropoietic Biomarkers in Response to Treatment With Erythropoietin in Belgrade Rats.

Frontiers in pharmacology

Ly M Nguyen, Aman P Singh, Pawel Wiczling, Wojciech Krzyzanski

Affiliations

  1. Department of Pharmaceutical Sciences, The State University of New York at Buffalo, Buffalo, NY, United States.
  2. Department of Biopharmaceutics and Pharmacodynamics, Medical University of Gda?sk, Gda?sk, Poland.

PMID: 29692726 PMCID: PMC5902559 DOI: 10.3389/fphar.2018.00316

Abstract

Recombinant human erythropoietin (rHuEPO) is used effectively in the treatment of various anemic disorders. Belgrade rat is a useful animal model of anemia caused by defect in iron utilization. The objective of the present study was to investigate the dynamics of erythropoietic biomarkers in Belgrade rats receiving rHuEPO. Pharmacokinetics of rHuEPO was evaluated in Belgrade rats and normal rats after intravenous administration of single doses of the drug (100 and 1350 IU/kg). Pharmacodynamic biomarkers included levels of red blood cells, hemoglobin, and reticulocytes following administration of a single intravenous dose of rHuEPO (100 IU/kg). Red blood cell survival was assessed after treatment with rHuEPO (450 IU/kg), three times a week for 2 weeks. It was found that rHuEPO exhibited non-linear pharmacokinetics in both Belgrade and control rats. At the low dose, plasma concentrations and AUC (area under the curve) were significantly lower while clearance and volume of distribution were higher in Belgrade rats (

Keywords: DMT1; anemia; iron utilization; pharmacodynamics; pharmacokinetics; red blood cell survival

References

  1. J Pharmacol Exp Ther. 1997 Nov;283(2):520-7 - PubMed
  2. J Pharmacol Exp Ther. 2010 Sep 1;334(3):897-910 - PubMed
  3. Mol Cell Biol. 1994 Jun;14(6):4183-92 - PubMed
  4. Blood Cells Mol Dis. 2011 Dec 15;47(4):243-8 - PubMed
  5. Am J Kidney Dis. 1989 Aug;14(2 Suppl 1):9-13 - PubMed
  6. J Pharmacokinet Pharmacodyn. 2007 Dec;34(6):849-68 - PubMed
  7. J Pediatr. 2008 Jan;152(1):136-9 - PubMed
  8. Exp Hematol. 1992 Dec;20(11):1257-62 - PubMed
  9. Biochim Biophys Acta. 1999 Mar 8;1449(2):125-36 - PubMed
  10. J Cell Physiol. 1999 Mar;178(3):349-58 - PubMed
  11. J Cell Physiol. 1988 Oct;137(1):65-74 - PubMed
  12. Eur J Pharm Sci. 2005 Nov;26(3-4):295-306 - PubMed
  13. Am J Hematol. 2018 Mar;93(3):E58-E60 - PubMed
  14. Blood Cells. 1988;14(1):47-67 - PubMed
  15. Exp Hematol. 2008 Dec;36(12):1573-84 - PubMed
  16. Exp Hematol. 1989 Aug;17(7):812-5 - PubMed
  17. Biometals. 1997 Apr;10(2):65-76 - PubMed
  18. J Am Soc Nephrol. 1996 Aug;7(8):1178-82 - PubMed
  19. Hematol Cell Ther. 1997 Dec;39(6):307-16 - PubMed
  20. Genetics. 1966 Jun;53(6):1079-89 - PubMed
  21. Proc Natl Acad Sci U S A. 1998 Feb 3;95(3):1148-53 - PubMed
  22. Biochim Biophys Acta. 2012 Sep;1823(9):1434-43 - PubMed
  23. Arzneimittelforschung. 1992 Feb;42(2):174-8 - PubMed
  24. Ann Hematol. 1993 Aug;67(2):81-7 - PubMed
  25. Blood. 1991 Jun 15;77(12):2583-90 - PubMed
  26. J Pharmacol Exp Ther. 2006 Dec;319(3):1297-306 - PubMed
  27. J Pharm Sci. 1995 Jun;84(6):760-7 - PubMed
  28. J Clin Invest. 1987 Aug;80(2):357-66 - PubMed
  29. J Formos Med Assoc. 2014 Jan;113(1):3-10 - PubMed
  30. J Am Soc Nephrol. 2012 Oct;23(10):1631-4 - PubMed
  31. ASAIO Trans. 1990 Jul-Sep;36(3):M691-6 - PubMed

Publication Types

Grant support